Biogen(US:BIIB)2025-06-17 14:00Financial Data and Key Metrics Changes - The company reported a strong performance with a majority of shares present or represented by proxy, confirming a quorum for conducting business [4] - Preliminary voting results indicated that all 11 director nominees were elected to the Board of Directors for a one-year term [14] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting Company Strategy and Development Direction and Industry Competition - The company aims to pursue long-term sustainable growth and is focused on strengthening and diversifying its portfolio [15] - Management expressed optimism about the upcoming year and the potential for growth under current leadership [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the exciting times ahead for the company and the commitment to improving patient lives [15] Other Important Information - PricewaterhouseCoopers was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025 [14] - An advisory vote on executive compensation received majority support from stockholders [14] Q&A Session Summary Question: How does the compensation committee use the compensation actually paid total compensation figures in its calculation of the CEO target total compensation award for the upcoming year? - The Compensation Committee considers competitive factors and performance incentives in setting executive compensation, but the compensation actually paid is not directly used to determine the following year's total compensation [10][11] - The committee ensures that the compensation program aligns with stockholder interests [11] Question: Are there any further questions from stockholders on the proposals brought before this meeting? - No further questions were raised by stockholders [12]